300871.SZ SHZ
Hvsen Biotechnology Co., Ltd.
1W: -2.8%
1M: -6.4%
3M: -9.7%
YTD: -22.1%
1Y: -7.9%
3Y: +27.2%
5Y: -48.0%
¥21.10 ($3.15)
+0.48 (+2.33%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$1.2B
+17.7% ▲
5Y CAGR: +23.0%
Gross Profit
$196M
-6.6% ▼
5Y CAGR: +3.7%
Operating Income
-$29M
-292.8% ▼
Net Income
-$20M
-220.1% ▼
EPS (Diluted)
$-0.12
-220.0% ▼
EBITDA
$127M
-21.3% ▼
5Y CAGR: +6.3%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $777M | $996M | $1.0B | $1.0B | $1.2B |
| YoY Growth | +82.0% | +28.1% | +2.7% | -0.3% | +17.7% |
| Cost of Revenue | $490M | $725M | $798M | $810M | $1.0B |
| Gross Profit | $288M | $271M | $225M | $210M | $196M |
| Gross Margin | 37.0% | 27.2% | 22.0% | 20.6% | 16.3% |
| R&D Expenses | $28M | $47M | $40M | $28M | $56M |
| SG&A Expenses | $66M | $64M | $60M | $34M | $40M |
| Operating Expenses | $110M | $135M | $146M | $195M | $225M |
| Operating Income | $177M | $151M | $59M | $15M | -$29M |
| Operating Margin | 22.7% | 15.2% | 5.8% | 1.5% | -2.4% |
| Interest Expense | $3M | $3M | $19M | $28M | $43M |
| Income Before Tax | $176M | $151M | $57M | $12M | -$29M |
| Tax Expense | $26M | $18M | $4M | -$4M | -$9M |
| Net Income | $150M | $133M | $53M | $17M | -$20M |
| Net Margin | 19.3% | 13.3% | 5.2% | 1.6% | -1.7% |
| EPS (Diluted) | $0.91 | $0.80 | $0.32 | $0.10 | $-0.12 |
| EBITDA | $198M | $183M | $138M | $161M | $127M |
| Shares Outstanding | 166M | 166M | 165M | 166M | 166M |